ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIALFIBRILLATION WITH ACUTE CORONARY SYNDROME AFTERPERCUTANEOUS CORONARY INTERVENTION. REVIEW.

Abstract

Introduction. The review is devoted to the issues of antithrombotic combinations in patients with atrial fibrillation (AF)
who underwent percutaneous coronary intervention (PCI) and stenting.
Objective: To analyze the main literature and clinical recommendations on the efficacy and safety of antithrombotic
combinations in patients with AF who have undergone PCI and stenting.
Search strategy. The search for scientific publications was carried out in the search engines PubMed, Web of Science,
Google Scholar, in the electronic scientific libraries eLibrary, CyberLeninka. The search depth is 15 years (2006-2021).
Search for information on the efficacy and safety of antithrombotic combinations in patients with AF who have undergone
PCI and stenting.

Results. There are currently a lot of studies comparing the use of oral anticoagulants (OAC) in patients with AF after
PCI. With the appearance of the results of large randomized trials, the recommendations for antithrombotic therapy in this
category of patients have been updated. We aim to analyze the currently available literature on the problem of TAT and DAT
in patients with AF and acute coronary syndrome (ACS), and provide data on the risks and benefits.
Conclusions. A review of the current literature on antithrombotic therapy in patients with AF who have undergone PCI
and subsequent coronary artery stenting shows that the preferred regimen is double antithrombotic therapy (DAT) consisting
of a P2Y12 inhibitor in combination with UAC, and triple antithrombotic therapy (TAT) exposes them to an increased risk of
bleeding. Decisions regarding specific agents and duration of treatment should be based on thrombotic risk, bleeding risk
and patient preferences.